Skip to main content
SpringerLink
Log in

Neutralization of the Cytotoxic Effect of Anti-αGal Antibodies with Monoclonal Anti-idiotypic Antibodies

  • Chapter
Xenotransplantation

  • 188 Accesses

Abstract

The use of the pig (or other widely divergent species) as a donor of organs for humans is dependent upon the development of a successful method of overcoming the hyperacute rejection (as well as any subsequent immune response) that is mounted in humans against grafted pig organs. The initiating factor in this hyperacute rejection is believed to be the presence of preformed antibodies in the recipient’s serum [1–4]. Recipient xenoreactive antibodies bind target molecules on the vascular endothelial cell surface of the xenografted organ and activate complement, leading to endothelial cell destruction and resulting in interstitial hemorrhage and edema.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Rosenberg, J.C., Hawkins, E., Rector, F. Mechanisms of immunological injury during antibody-mediated hyperacute rejection of renal heterografts. Transplantation, 1971; 11:151

    Article  PubMed  CAS  Google Scholar 

  2. Hammer, C, Chaussey, C.H., Brendel, W. Preformed natural antibodies in animals and man. Outlook on xenotransplantation. Eur. Surg. Res., 1973; 5:162

    Article  PubMed  CAS  Google Scholar 

  3. Paul, L.C. Mechanism of humoral xenograft rejection. In: Cooper, D.K.C., et al., (eds) Xenotransplantation. Springer, Heidelberg, 1991, p. 47

    Google Scholar 

  4. Piatt, J.L. Bach, F.H. Mechanism of tissue injury in hyperacute xenograft rejection. In: Cooper, D.K.C., et al., (eds) Xenotransplantation. Springer, Heidelberg, 1991, p. 69

    Google Scholar 

  5. Good, A.H., Cooper, D.K.C., Malcolm, A.J., et al. Identification of carbohydrate structures that bind human antiporcine antibodies: implications for discordant xengrafting in humans. Transplant. Proc, 1992; 24:559

    PubMed  CAS  Google Scholar 

  6. Cooper, D.K.C., Good, A.H., Koren, E., et al. Identification of a-galactosyl and other carbohydrates that are bound by human anti-pig antibodies: relevance to discordant xenografting in man. Transplant. Immunol., 1993; 1:198

    Article  CAS  Google Scholar 

  7. Cooke, A. Regulation of the immune response. In: Roitt, L, et al. (eds) Immunology. Mosby-Year Book, Europe, Ltd., London, 1993, p. 94

    Google Scholar 

  8. Koren E, Milotic F, Neethling FA, Koscec M, Fei D, Kobayashi T, Taniguchi S, Cooper DKC. Murine monoclonal anti-idiotypic antibodies directed against human anti-αGal antibodies reduce in vitro and in vivo cytotoxicity of human and baboon sera to pig cells in culture: implications for pig-to-human organ xenotransplantation. Transplantation, 1996; 62:837

    Article  PubMed  CAS  Google Scholar 

  9. Goding, J.W. Production of monoclonal antibodies. In: Goding, J.W. Monoclonal Antibodies: Principles and Practice. Academic Press, London, 1986, p.71

    Google Scholar 

  10. Koren, E., Kujundzic, M., Koscec, M., et al. Cytotoxic effects of human preformed anti-Gal IgG and complement on cultured pig cells. Transplant. Proc, 1994; 26:1336

    PubMed  CAS  Google Scholar 

  11. Kujundzic, M., Koren, E., Neethling, F.A., et al. Variability of anti-αGal antibodies in human serum and their relation to serum cytotoxicity against pig cells. Xenotransplantation, 1994; 1:58

    Article  Google Scholar 

  12. Galili, U., Macher, B.A., Buehler, J., Shohet, S.B. Human natural anti-α-galactosyl IgG. II. The specific recognition of α(1–3)-linked galactose residues. J.Exp.Med., 1985; 162:573

    Article  PubMed  CAS  Google Scholar 

  13. Miyajima, T., Higuchi, R., Kashiwabara, H., Yokoyama, T., Fujimoto, S. Anti-idiotypic antibodies in a patient with a functioning renal graft. Nature, 1980; 283:306

    Article  PubMed  CAS  Google Scholar 

  14. Pohanka, E., Manfro, R.C., Oto, C, et al. Anti-idiotypic antibodies to HLA after donor-specific blood transfusion (DST). Transplant. Proc, 1989; 21:1806

    PubMed  CAS  Google Scholar 

  15. Reed, E., Hardy, M., Benvenisty, A., et al. Effect of anti-idiotypic antibodies to HLA on graft survival in renal allograft recipients. New Engl. J. Med., 1987; 316:1450

    Article  PubMed  CAS  Google Scholar 

  16. Rodey, G.A., Phelan, D.L. Association of anti-idiotypic antibody with successful second transplant of a kidney sharing HLA antigens with the previous hyperacutely rejected first kidney. Transplantation, 1989; 48:54

    Article  PubMed  CAS  Google Scholar 

  17. Ye Y, Neethling, F.A., Niekrasz, M., et al. Intravenous administration of a-galactosyl carbohydrates reduces in vivo baboon serum cytotoxicity to pig kidney cells and transplanted pig hearts. Transplant. Proc, 1994; 26:1399

    PubMed  CAS  Google Scholar 

  18. Kobayashi, T., Taniguchi, S. Ye, Y et al. Prolongation of graft survival following pig-to-baboon heart transplantation by cobra venom factor (CVF) without natural antibody depletion. Submitted for publication

    Google Scholar 

  19. Cooper, D.K.C., Ye, Y, Niekrasz N, , et al. Specific intravenous carbohydrate therapy - a new concept in inhibiting antibody-mediated rejection: experfience with ABO-incom-patible cardiac allografting in the baboon. Transplantation, 1993; 56:769

    Article  PubMed  CAS  Google Scholar 

  20. Bannett, A.D., McAlack, R.F., Raja, R., et al. Experiences with known ABO-mismatched renal transplants. Transplant. Proc, 1987; 19:4543

    PubMed  CAS  Google Scholar 

  21. Adair, J.R. Engineering antibodies for therapy. Immunol Rev., 1992; 130:5

    Article  PubMed  CAS  Google Scholar 

  22. Jolliffe, L.K. Humanized antibodies: enhancing therapeutic utility through antibody engineering. Int. Rev. Immunol., 1993; 10:241

    Article  PubMed  CAS  Google Scholar 

  23. Woodie, E.S., Thistlewaite, J.R., Jolliffe, L.K., et al. Humanized antibodies: successful transfer of immune modulating properties and idiotype expression. J. Immunol., 1992; 148:2756

    Google Scholar 

  24. Ghetie, V., Swindell, E., Uhr, J.W., Vitetta, E.S. Purification and properties of immuno-toxins containing one vs two deglycosylated ricin A chains. J. Immunol. Methods., 1993; 166:117

    Article  PubMed  CAS  Google Scholar 

  25. Amlot, P.L., Stone, MJ., Cunningham, D., et al. A phase I study of an anti-CD22-degly-cosylated ricin A chain immunotoxin in the treatment of B-cell lymphomas resistant to conventional therapy. Blood, 1993; 82:2624

    Google Scholar 

  26. Grossbard, M.L., Gribben, J.G., Freedman, A.S., et al. Adjuvant immunotoxin therapy with anti-B4-blocked ricin after autologous bone marrow transplantation for patients with B-cell non-Hodgkin’s lymphoma. Blood, 1993; 81:2263

    Google Scholar 

Download references

Authors
  1. E. Koren
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. F. Milotic
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. F. A. Neethling
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. D. K. C. Cooper
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Immunologist (Surgery), Transplantation Biology Research Center, Massachusetts General Hospital, Harvard Medical School, 02129, Boston, Massachusetts, USA

    David K. C. Cooper M.A., M.D., Ph.D., M.S., F.R.C.S. (Associate Member, Scientific Staff) (Associate Member, Scientific Staff)

  2. Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma, USA

    David K. C. Cooper M.A., M.D., Ph.D., M.S., F.R.C.S. (Associate Member, Scientific Staff) (Associate Member, Scientific Staff)

  3. Department of Nephrology, Odense University Hospital, 5000, Odense, Denmark

    Ejvind Kemp M.D. (Professor and Head) (Professor and Head)

  4. Departments of Surgery, Pediatrics and Immunology, Duke University Medical Center, Durham, NC, 27710, USA

    Jeffrey L. Platt M.D. (Joseph W. and Dorothy W. Beard Professor) (Joseph W. and Dorothy W. Beard Professor)

  5. Department of Surgery, University of Cambridge, Cambridge, CB22QQ, UK

    David J. G. White M.A., Ph.D., M.R.C.Path (Immunologist and Lecturer, Director of Research and Development) (Immunologist and Lecturer, Director of Research and Development)

  6. Imutran Laboratories, Cambridge, UK

    David J. G. White M.A., Ph.D., M.R.C.Path (Immunologist and Lecturer, Director of Research and Development) (Immunologist and Lecturer, Director of Research and Development)

Rights and permissions

Reprints and permissions

Copyright information

© 1997 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Koren, E., Milotic, F., Neethling, F.A., Cooper, D.K.C. (1997). Neutralization of the Cytotoxic Effect of Anti-αGal Antibodies with Monoclonal Anti-idiotypic Antibodies. In: Cooper, D.K.C., Kemp, E., Platt, J.L., White, D.J.G. (eds) Xenotransplantation. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-60572-7_27

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-60572-7_27

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-64460-3

  • Online ISBN: 978-3-642-60572-7

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation